Zim Laboratories Approves Unaudited Financial Results for Quarter Ended June 30, 2026
Zim Laboratories Limited announced the outcomes of its Board meeting held on August 6, 2026, confirming the approval of its unaudited financial results for the quarter ended June 30, 2026. The Consolidated and Standalone statements were subjected to a limited review by Deloitte Haskins & Sells LLP.The company's consolidated performance demonstrated mixed trends across the respective periods. For the quarter ended June 30, 2026, Total income stood at 9,517.08 (in lakhs). This followed by expenses totaling 10,074.38, resulting in a loss before tax of (557.30) and a net profit after tax attributable to owners of (401.68).
The performance metrics for the consolidated entity across all four periods are detailed below:
| Particulars | 30 June 2026 (Unaudited) | 31 March 2026 (Unaudited) | 30 June 2025 (Unaudited) | 31 March 2026 (Audited) |
|---|---|---|---|---|
| Revenue from operations | 9,417.85 | 10,527.34 | 7,175.61 | 37,440.01 |
| Total income | 9,517.08 | 11,143.55 | 7,323.24 | 38,578.31 |
| Total expenses | 10,074.38 | 10,649.38 | 7,566.44 | 37,757.03 |
| Net Profit/(loss) after tax attributable to Owners | (401.68) | 373.98 | (187.49) | 583.81 |
| EPS Basic Diluted | (0.75) | N/A | (0.38) | 1.19 |
Standalone Financial Results
Focusing on the company's standalone results, Zim Laboratories reported Total income of 9,403.38 in lakhs for the quarter ended June 30, 2026. The entity recorded total expenses of 9,945.60, leading to a profit before tax loss of (542.22).For the standalone segment, key financial data points are as follows:
| Particulars | 30 June 2026 (Unaudited) | 31 March 2026 (Unaudited) | 30 June 2025 (Unaudited) | 31 March 2026 (Audited) |
|---|---|---|---|---|
| Revenue from operations | 9,304.83 | 10,285.37 | 7,142.77 | 37,048.15 |
| Total income | 9,403.38 | 10,901.23 | 7,290.33 | 38,187.14 |
| Total expenses | 9,945.60 | 10,448.69 | 7,518.62 | 37,347.12 |
| Net Profit/(loss) after tax | (387.55) | 328.21 | (169.19) | 596.52 |
| EPS Basic Diluted | (0.72) | N/A | (0.35) | 1.22 |
These results were prepared in accordance with the recognition and measurement principles of Indian Accounting Standard 34, Interim Financial Reporting, and are subject to a limited review by the statutory auditor. The company operates principally within the pharmaceuticals segment.
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.